Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy L Cannon

Showing results (11-20 of 30) with videos related to

Pageof 3
Sort By:
NPJ Precision Oncology|September 14, 2024
Proteomics based selection achieves complete response to HER2 therapy in HER2 IHC 0 breast cancerLaura E Johnston, Jamie Randall, Safae Chouraichi, et al.
NPJ Precision Oncology|March 5, 2026
Pan-cancer multi-omic ERBB2-HER2 characterization using next-generation sequencing and quantitative proteomicsAllison L Hunt, Jamie Randall, Jonathan D Ogata, et al.
JCO Oncology Practice|April 1, 2021
Remote Home Monitoring of Patients With Cancer During the COVID Pandemic: A Pilot StudyMary Steimer, Jessica Leabo, Hongkun Wang, et al.
Clinical Proteomics|March 21, 2024
Quantitative proteomic analysis of HER2 protein expression in PDAC tumorsJamie Randall, Allison L Hunt, Aratara Nutcharoen, et al.
European Journal of Cancer (Oxford, England : 1990)|March 11, 2025
Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancerChangsong Qi, Lin Shen, Thierry Andre, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 30, 2024
Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of <i>KRAS</i>-Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II TrialDaniel H Ahn, Maya Ridinger, Timothy L Cannon, et al.
NPJ Precision Oncology|April 15, 2025
Real-time functional proteomics enhances therapeutic targeting in precision oncology molecular tumor boardsAllison L Hunt, Jamie Randall, Mahesh M Mansukhani, et al.
Cancer Epidemiology|May 1, 2026
Advanced adenomas among young endurance runners: A prospective hypothesis-generating prevalence studyWhitney R Swain, Selena Bonomelli, Laura Johnston, et al.
JCO Precision Oncology|November 21, 2022
Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With <i>BRAF</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyKelsey A Klute, Michael Rothe, Elizabeth Garrett-Mayer, et al.
Targeted Oncology|October 22, 2020
Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyJulie G Fisher, David Tait, Elizabeth Garrett-Mayer, et al.
Pageof 3

Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
NPJ Precision Oncology|September 14, 2024
Proteomics based selection achieves complete response to HER2 therapy in HER2 IHC 0 breast cancerLaura E Johnston, Jamie Randall, Safae Chouraichi, et al.
NPJ Precision Oncology|March 5, 2026
Pan-cancer multi-omic ERBB2-HER2 characterization using next-generation sequencing and quantitative proteomicsAllison L Hunt, Jamie Randall, Jonathan D Ogata, et al.
JCO Oncology Practice|April 1, 2021
Remote Home Monitoring of Patients With Cancer During the COVID Pandemic: A Pilot StudyMary Steimer, Jessica Leabo, Hongkun Wang, et al.
Clinical Proteomics|March 21, 2024
Quantitative proteomic analysis of HER2 protein expression in PDAC tumorsJamie Randall, Allison L Hunt, Aratara Nutcharoen, et al.
European Journal of Cancer (Oxford, England : 1990)|March 11, 2025
Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancerChangsong Qi, Lin Shen, Thierry Andre, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 30, 2024
Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of <i>KRAS</i>-Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II TrialDaniel H Ahn, Maya Ridinger, Timothy L Cannon, et al.
NPJ Precision Oncology|April 15, 2025
Real-time functional proteomics enhances therapeutic targeting in precision oncology molecular tumor boardsAllison L Hunt, Jamie Randall, Mahesh M Mansukhani, et al.
Cancer Epidemiology|May 1, 2026
Advanced adenomas among young endurance runners: A prospective hypothesis-generating prevalence studyWhitney R Swain, Selena Bonomelli, Laura Johnston, et al.
JCO Precision Oncology|November 21, 2022
Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With <i>BRAF</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyKelsey A Klute, Michael Rothe, Elizabeth Garrett-Mayer, et al.
Targeted Oncology|October 22, 2020
Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyJulie G Fisher, David Tait, Elizabeth Garrett-Mayer, et al.
Pageof 3